↓ Skip to main content

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

Overview of attention for article published in The Lancet, January 2017
Altmetric Badge
583

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Citations

dimensions_citation
1543 Dimensions

Readers on

mendeley
910 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
Published in
The Lancet, January 2017
DOI 10.1016/s0140-6736(16)32409-6
Pubmed ID
Authors

John P Neoptolemos, Daniel H Palmer, Paula Ghaneh, Eftychia E Psarelli, Juan W Valle, Christopher M Halloran, Olusola Faluyi, Derek A O'Reilly, David Cunningham, Jonathan Wadsley, Suzanne Darby, Tim Meyer, Roopinder Gillmore, Alan Anthoney, Pehr Lind, Bengt Glimelius, Stephen Falk, Jakob R Izbicki, Gary William Middleton, Sebastian Cummins, Paul J Ross, Harpreet Wasan, Alec McDonald, Tom Crosby, Yuk Ting, Kinnari Patel, David Sherriff, Rubin Soomal, David Borg, Sharmila Sothi, Pascal Hammel, Thilo Hackert, Richard Jackson, Markus W Büchler, European Study Group for Pancreatic Cancer

X Demographics

X Demographics

The data shown below were collected from the profiles of 186 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 910 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 2 <1%
United Kingdom 2 <1%
Czechia 2 <1%
Brazil 1 <1%
Spain 1 <1%
United States 1 <1%
Unknown 901 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 125 14%
Student > Ph. D. Student 100 11%
Other 98 11%
Student > Bachelor 82 9%
Student > Doctoral Student 76 8%
Other 169 19%
Unknown 260 29%
Readers by discipline Count As %
Medicine and Dentistry 400 44%
Biochemistry, Genetics and Molecular Biology 74 8%
Agricultural and Biological Sciences 37 4%
Pharmacology, Toxicology and Pharmaceutical Science 20 2%
Nursing and Health Professions 19 2%
Other 62 7%
Unknown 298 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 583. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 February 2024.
All research outputs
#41,397
of 26,007,325 outputs
Outputs from The Lancet
#815
of 43,261 outputs
Outputs of similar age
#893
of 426,535 outputs
Outputs of similar age from The Lancet
#15
of 460 outputs
Altmetric has tracked 26,007,325 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 43,261 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 68.2. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 426,535 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 460 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.